TERGETED TGF� INHIBITION
This invention relates generally to bifunctional molecules including (a) a TGFBRII or fragment thereof capable of binding TGFB and (b) an antibody, or antigen binding fragment thereof, that binds to an immune checkpoint protein, such as Programmed Death Ligand 1 (PD-L1), uses of such molecules (e.g....
Saved in:
Main Author | |
---|---|
Format | Patent |
Language | English |
Published |
03.10.2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | This invention relates generally to bifunctional molecules including (a) a TGFBRII or fragment thereof capable of binding TGFB and (b) an antibody, or antigen binding fragment thereof, that binds to an immune checkpoint protein, such as Programmed Death Ligand 1 (PD-L1), uses of such molecules (e.g., for treating cancer), and methods of making such molecules. |
---|---|
Bibliography: | Application Number: PH20161501549 |